{"id":"chemotherapy-then-hormonotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combination treatment strategy rather than a single drug. Chemotherapy works through cytotoxic mechanisms to kill rapidly dividing cancer cells, while subsequent hormonotherapy (endocrine therapy) blocks hormone receptors or reduces hormone production to prevent recurrence and growth of hormone-sensitive cancer cells. The sequential approach aims to maximize efficacy by first debulking the tumor, then maintaining control through hormonal suppression.","oneSentence":"A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:34.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (likely primary indication based on UNICANCER focus)"}]},"trialDetails":[{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":615,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CHEMOTHERAPY then HORMONOTHERAPY","genericName":"CHEMOTHERAPY then HORMONOTHERAPY","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth. Used for Hormone receptor-positive breast cancer (likely primary indication based on UNICANCER focus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}